Acadia Pharma (ACAD) Tops Q3 EPS by 17c
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $25.43 +7.21%
Revenue Growth %: +12.1%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
CGEH, NAKA, APOG, More
Revenue Growth %: +12.1%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
CGEH, NAKA, APOG, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q3 EPS of ($0.09), $0.17 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $131.6 million versus the consensus estimate of $127.75 million.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
- EU panel backs Acadia's Rett syndrome drug trofinetide for approval
- Hyperscale Data acquires 48.5 acres to expand Michigan campus
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
